Earlier this week, the United States Food and Drug Administration (FDA) approved a human trial for a blueberry-sized brain ...

The newly approved device aims to treat depression by directly stimulating neural activity.

Brain implant gets FDA clearance for first wireless depression treatment trial, offering battery-free stimulation in ...

FDA approved a request from Motif Neurotech, to start an initial feasibility trial to test a brain implant to treat ...

Motif Neurotech For decades, doctors have tried to treat depression with electricity. Now, a Houston startup wants to ...

A device the size of a blueberry is hypothesized to give people with treatment-resistant depression another option — and the FDA is giving its Houston maker a chance to test it.

While many brain-computer interface companies are focused on helping paralyzed people communicate, Motif Neurotech is ...

Motif’s study primarily aims to validate the safety of its XCS system over a 12-month period following implantation.

The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies ...

The FDA’s move follows an executive order from President Donald Trump earlier this month that paved the way for more ...

The first drug for women suffering postpartum depression received federal approval on Tuesday, a move likely to pave the way for a wave of treatments to address a debilitating condition that is the ...

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson‘s Caplyta as an add-on treatment for adults with major depressive disorder. Following the FDA’s Nov. 5 decision ...